16Sep 2022
Should patients with non‐muscle‐invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette–Guérin?

Should patients with non‐muscle‐invasive bladder cancer discontinue fibrin clot inhibitors during bacille Calmette–Guérin?

To determine the impact of fibrin clot inhibitor (FCI) use on oncological outcomes in a large contemporary cohort of patients with non‐muscle‐invasive bladder cancer (NMIBC) treated with adequate bacille Calmette–Guérin (BCG). Overall, 226 of 526 patients (43.0%) used an FCI: aspirin (205), clopidogrel (38), warfarin (18) and novel oral anticoagulant (NOAC; seven). The use of FCIs was not associated with adverse oncological outcomes in a large contemporary cohort of patients receiving adequate intravesical BCG for NMIBC. Based on these results, FCIs may be safely continued during BCG immunotherapy.

  • #urology

Like

Save

Share